Lisa Tachiki, MD
@LisaTachiki
Followers
71
Following
24
Media
1
Statuses
19
Assistant Professor in Medical Oncology Melanoma/Renal Cancers @UWMedicine @fredhutch All opinions are my own.
Joined April 2023
Excited to share this paper we’ve been working on for some time. Immunotherapy discontinuation appears to be associated with high rates of Merkel cell progression in our cohort. @jitcancer
jitc.bmj.com
Background Immune checkpoint inhibitors (ICIs) are the preferred systemic therapy for most patients with advanced Merkel cell carcinoma (MCC). However, the optimal duration of treatment for patients...
0
0
2
Dear Colleagues, The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 for #Melanoma This List Curated by: #OncoAlertAF Leads : @anmwongNZ 🇳🇿 @weoncologists 🇺🇸 and @OncoAlert #Melanoma Faculty @DrBetofMDPhD 🇺🇸 TOP 11 Abstracts Neoadjuvant
0
15
37
My top themes of #ASCO24 for #kidneycancer, #prostatecancer, #bladdercancer, & #DevelopmentalIO -- scratches only the surface of the bountiful harvest of ASCO trials!! Looking forward to seeing/hearing from colleagues from around the world @ASCO @myESMO @OncoAlert
2
71
146
It is out ! @OncoAlert @tompowles1
KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery. https://t.co/oVQXvyffL4
5
25
149
Suzzanne Lacey's stage 4 #kidneycancer diagnosis was no match for a potent blend of #immunotherapy, including a unique approach to reduced-frequency dosing. “It worked for her,” said Lacey's oncologist, @EvanHallMD.
fredhutch.org
A stage 4 kidney cancer diagnosis was no match for a potent blend of immunotherapy, including a unique approach to reduced-frequency dosing.
1
1
3
Every dose of an #ImmuneCheckpointInhibitor takes time and money. A new study from @LisaTachiki, @BhatiaS_MD and others shows that reducing the frequency of #ICI doses can save patients and the health care system time and money.
2
3
7
And finally… @EvanHallMD @fredhutch with update on refractory #kidneycancer @OncLiveSOSS, focusing on cabozantinib & belzutifan data. Another one to follow! @KidneyCancer @kcCURE @kidneycan @PGrivasMDPhD @LisaTachiki #EvanYu
0
3
9
Comprehensive discussion from #ScottTykodi @fredhutch on 1st line metastatic #kidneycancer @OncLiveSOSS! Always helpful and thoughtful overview on data &patient selection. @PGrivasMDPhD @LisaTachiki @EvanHallMD #EvanYu @kcCURE @KidneyCancer @kidneycan
0
5
12
Every dose of an #ImmuneCheckpointInhibitor takes time and money. A new study from @LisaTachiki, @BhatiaS_MD and others shows that reducing the frequency of #ICI doses can save patients and the health care system time and money.
0
2
3
Thank you @BhatiaS_MD @EvanHallMD @PaulNghiem for your mentorship on this project and to all our coauthors for your work! So happy to be able to share our experience through this manuscript!!
0
2
7
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
2
98
248
My colleague @HibaMKhanMD gave a meaningful talk @ASCO this morning, highlighting a higher risk for mortality in patients who experience adverse financial events. It's also interesting to see the risk of death among common cancer types.
1
5
12
The cost of immune checkpoint inhibitors: $170,000 per patient per year. Less than 5% of eligible patients in LMIC are able to afford/access ICIs. Dr Lisa Tachiki of @fredhutch discusses the ways to expand ICI access globally at #SCHD2023
0
8
17
Fantastic to host the stellar @brian_rini @Uromigos in Seattle for Grand Rounds. We started with delicious dinner & great company @EvanHallMD @LisaTachiki @DRBakaloudiMD #Tykodi reviewed RCC, clinical research, leadership @fredhutch @tompowles1 @BhatiaS_MD @mshadman @OncoAlert
0
5
34
Fantastic @brian_rini talk #AUA23 on nccRCC! Biomarker development & clinical trials remain essential! Nice shout out to @montypal PAPMET trial & launched @SWOG 2200 trial & data on savolitinib @DrChoueiri @OncoAlert @neerajaiims @UroOnc @KidneyCancer @EvanHallMD @LisaTachiki
0
15
48
Congratulations @BhatiaS_MD on your distinguished faculty award! Well deserved! Thank for you hosting such a beautiful gala for such an important cause! @btfoundation @binayshah
1
5
19
#SCHD23 learned a ton from my co-panelists @LisaTachiki @HibaMKhanMD @drkomanduri - some of these discussed ideas about de-escalating Tx dose/frequency will change the world some day! Thanks @btfoundation for inviting us and humoring my toddler ⚽️ analogy to drug development…
0
7
21
Cost is checkpoint inhibitor prohibitive for access to these drugs- @LisaTachiki of @fredhutch #SCHD23 @BhatiaS_MD @btfoundation @RahulBanerjeeMD
0
3
4